Kasherman Lawrence, Liu Shiru Lucy, Karakasis Katherine, Lheureux Stephanie
Department of Medical Oncology, St. George Hospital, Kogarah, NSW 2217, Australia.
St. George and Sutherland Clinical Schools, University of New South Wales, Sydney, NSW 2052, Australia.
Cancers (Basel). 2022 Feb 22;14(5):1122. doi: 10.3390/cancers14051122.
Since the discovery of angiogenesis and its relevance to the tumorigenesis of gynecologic malignancies, a number of therapeutic agents have been developed over the last decade, some of which have become standard treatments in combination with other therapies. Limited clinical activity has been demonstrated with anti-angiogenic monotherapies, and ongoing trials are focused on combination strategies with cytotoxic agents, immunotherapies and other targeted treatments. This article reviews the science behind angiogenesis within the context of gynecologic cancers, the evidence supporting the targeting of these pathways and future directions in clinical trials.
自从发现血管生成及其与妇科恶性肿瘤发生的相关性以来，在过去十年中已经开发了多种治疗药物，其中一些已成为与其他疗法联合使用的标准治疗方法。抗血管生成单药治疗的临床活性有限，正在进行的试验集中在与细胞毒性药物、免疫疗法和其他靶向治疗的联合策略上。本文回顾了妇科癌症背景下血管生成背后的科学、支持靶向这些途径的证据以及临床试验的未来方向。
